Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
ARKGvsXBIETF Comparison
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. ARKG's top 3 sector exposures are Health Care and Information Technology. In contrast, XBI's top sector exposures are Health Care ARKG is more expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.35% for XBI. ARKG is down -5.11% year-to-date (YTD) with -$10M in YTD flows. XBI performs better with -0.09% YTD performance, and -$580M in YTD flows. Run a side-by-side ETF comparison of ARKG and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
ARKG vs XBI performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG XBI | -3.62%-0.80% | -10.23%-0.49% | -5.11%-0.09% | +23.23%+42.26% | -2.84%+57.27% | -70.08%-17.29% |
| Flows | ARKG XBI | -$50M-$1.24B | -$85M-$513M | -$10M-$580M | -$210M-$505M | -$627M-$2.17B | -$2.79B+$935M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG XBI | +39.15%+26.47% | +44.62%+28.17% | +42.26%+27.29% | +45.19%+32.93% |
| Max drawdown | ARKG XBI | -19.50%-8.19% | -23.94%-21.44% | -51.98%-32.94% | -80.33%-57.63% |
| Max drawdown duration | ARKG XBI | 48d50d | 77d141d | 966d331d | 1822d1824d |
ARKG | XBI | |
Last sale 3/13/2026 at 1:30 PM | $26.36 | $121.83 |
| Previous close 03/12/2026 | $26.17 | $122.62 |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
ARKG | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
ARKG | XBI | |
|---|---|---|
| Last price | $26.36 | $121.83 |
| 1D performance | +0.73% | -0.64% |
| AuM | $1.11 B | $7.29 B |
| E/R | 0.75% | 0.35% |
ARKG | XBI | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | SPDR |
| Benchmark | - | S&P Biotechnology Select Industry Index |
| N° of holdings | 30 | 123 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | January 31, 2006 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the ARKG and XBI ETFs performed in 2026?
As of March 11, 2026, ARKG is down -5.11% year-to-date (YTD), while XBI has lost -0.09%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or XBI?
Year-to-date, the ARKG ETF saw -$10M in flows, compared to -$580M for XBI.
Which ETF is more volatile: ARKG or XBI?
Over the past year, ARKG had a volatility of 44.62%, while XBI experienced 28.17%.
Which ETF is bigger: ARKG or XBI?
As of March 11, 2026, ARKG holds $1.11 B in assets under management (AUM), while XBI manages $7.29 B.
What sectors do the ARKG and XBI ETFs invest in?
ARKG leans toward sectors like Health Care. Meanwhile, XBI focuses on Health Care.
What are the top holdings of the ARKG ETF and XBI ETF?
ARKG top holdings include CRISPR THERAPEUTICS, PERSONALIS INC and GUARDANT HEALTH INC. XBI holds in its top three: MODERNA INC, MIRUM PHARMACEUTICALS INC and REVOLUTION MEDICINES INC.
Which ETF is more diversified: ARKG or XBI?
ARKG holds 30 securities with 63.79% of its assets in the top 15. XBI has 149 securities and a top 15 weight of 21.6%.
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
Are Biotechnology ETFs In the Midst of a Comeback?
Two biotech ETFs to watch for the rest of 2022 and beyond
Biotech ETFs – Investing in Health Innovation
Active Trader Report: Use of Leveraged & Inverse ETFs Way Up
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
